The Grünenthal Group
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany.
Building on its unique position in pain treatment, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation. Grünenthal is one of the last remaining five research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. These investments amounted to about 27 percent of revenues in 2013.
BIO International Convention,
June 23-26, 2014, San Diego, USA
End of June, more than 15,000 visitors from all over the world and approx. 5,000 participating companies from over 62 countries meet in San Diego to discuss partnering opportunities.
In 2013 Grünenthal invested approximately 27 % of its revenues in R&D, with the objective of building strategic collaborations and it now presents its pipeline and assets for the third time.The new approach to M&A will be shared by Philipp von Gallwitz, CEO Grünenthal Inc with the biotech community on June 24th, at 10:45 am (Solana Beach presentation room). A new initiative, called the Innovative Medicines Unit (IMU), will be unveiled at the German BIO.NRW booth # 4413.